在PCI后早期口服抗凝单疗法:POEM试验的见解
Carlo A Pivato1, Gianluca Mincione1, Leon Gramss1
1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Cardio Center, IRCCS Humanitas Research Hospital, Milan, Italy.
American heart journal
|November 21, 2025
概括
对于经皮冠状动脉干预后高出血风险的患者,一个月的口服抗凝剂 (OAC) 疗法显示出低缺血和出血风险. 这支持早期OAC单疗法作为进一步研究的可行策略.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在高出血风险 (HBR) 患者的皮肤冠状动脉干预 (PCI) 需要缩短双抗血小板治疗 (DAPT).
- 在PCI后需要口服抗凝剂 (OAC) 的HBR患者的最佳抗血栓策略尚不清楚.
- POEM试验研究了HBR患者1个月的双重抗血栓治疗方案,重点关注需要OAC的患者.
研究的目的:
- 在接受PCI的HBR患者中评估1个月的双抗血栓治疗方案.
- 为了比较HBR患者的结局,有和没有OAC指示.
- 评估早期OAC单一治疗在这个患者群体中的可行性.
主要方法:
- 该POEM试验招募了使用生物可吸收聚合物Everolimus排泄支架治疗的HBR患者.
- 患者被分为非OAC (1个月的DAPT然后单抗血小板治疗) 和OAC (1个月的OAC + P2Y12抑制剂然后OAC单疗法) 组.
- 使用考克斯回归分析了时间到事件的结果,并进行了治疗意图和每条协议分析.
主要成果:
- 主要终点 (心脏死亡,心脏病发作,支架血栓形成) 在1年后发生在非OAC组的6.1%,OAC组的2.6% (HR 0.41).
- 二次性缺血的结果在各组之间是相似的.
- 出血事件 (BARC 3-5型) 是不常见的和可比的 (2.6%对1.3%).
结论:
- 在PCI后的HBR患者中,过渡到OAC单一治疗1个月后与低缺血和出血风险相关.
- 这种策略显示了与单一抗血小板治疗相似的结果.
- 早期OAC单一治疗似乎是可行的,需要进一步随机调查.
相关概念视频
Venous Thrombosis III: Interprofessional Care
268
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
268
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
286
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
286
Coronary Artery Disease V: Interprofessional Care
206
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
206


